Novavax (NVAX) Stock: Gaining On More Ebola Concerns

Novavax, Inc. (NASDAQ: NVAX) is off to an incredibly strong day in the market today, and for good reason. It has to do with yet another Ebola outbreak. While the outbreak is bad news for many, it’s great news for the company and its investors, who are excitedly pushing the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:54), NVAX is trading at $1.12 per share after a gain of $0.12 per share (12.00%) thus far today.

NVAX Gains As More Die From Ebola

As mentioned above, Novavax is having a strong day in the market today as news of an Ebola outbreak hit yesterday. According to the World Health Organization, 3 people have died from the outbreak, which is taking place in a remote northern region of the Democratic Republic of Congo. Health officials are currently finding their way to the Central African country as a rising number of suspected cases are coming down the wire.

Of course, any outbreak of a serious health threat is bad news overall. However, for NVAX, the news is proving to be positive. After all, the company is working to perfect a vaccine for the condition. At the moment, all data surrounding the vaccine is proving to be overwhelmingly positive. So, there’s good reason for the gains that we’re seeing today.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the company’s ongoing work with regard to Ebola, as well as the current outbreak taking place in the Democratic Republic of Congo. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required

Add Comment